Alizapride

Alizapride

Systematic (IUPAC) name
N-[(1-Allylpyrrolidin-2-yl)methyl]-6-methoxy-1H-benzo[d][1,2,3]triazole-5-carboxamide
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only)
Routes of administration	Oral, IM, IV
Pharmacokinetic data
Biological half-life	3 hours
Excretion	Renal
Identifiers
CAS Number	59338-93-1 Y
ATC code	A03FA05 (WHO)
PubChem	CID: 43008
DrugBank	DB01425 Y
ChemSpider	39202 Y
UNII	P55703ZRZY Y
KEGG	D07102 Y
ChEMBL	CHEMBL290194 Y
Chemical data
Formula	C16H21N5O2
Molecular mass	315.37 g/mol
SMILES O=C(c2cc1nnnc1cc2OC)NCC3N(C\C=C)CCC3
InChI InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20) Y Key:KSEYRUGYKHXGFW-UHFFFAOYSA-N Y
(verify)

Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.